Bicara Therapeutics Inc.

AI-generated fair value estimate for this company.

Method: rNPV = net cash $497.3M (no debt, as of 6/30/2026, funds operations into 1H2029) + risk-adjusted pipeline NPV of lead asset ficerafusp alfa (bifunctional EGFR/TGF-beta trap) in the pivotal Phase 3 FORTIFI-HN01 trial for 1L HNSCC. Assumed ~$3.5B unrisked peak global net sales given the large 1L HNSCC market, ~30% probability of approval (pivotal-stage asset with supportive Phase 2 data), ~10% discount rate -> risked pipeline NPV ~$700M. Total ~$1.2B / 66.17M shares outstanding ~ $18/share.

Reasoning: Bicara Therapeutics is a clinical-stage, pre-revenue biopharma (Nasdaq: BCAX), so intrinsic value is driven by its large net-cash cushion plus a probability-weighted valuation of its lead pivotal-stage oncology asset rather than a traditional cash-flow DCF.